{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:58:30Z","timestamp":1790539110458,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["J.C.K.-KENNED19AC0"],"award-info":[{"award-number":["J.C.K.-KENNED19AC0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:15:32Z","timestamp":1790421332000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) therapy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-5288","authenticated-orcid":false,"given":"John C.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderajew A.","family":"Taddesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Coppolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Cagnina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Cernadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvin S.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Kear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kubiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Keshk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Hackmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefi F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Algarawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan K","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Kerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Washko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary J","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Raby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Z.","family":"Uluer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.09.007_bib0001","first-page":"89","volume":"2025","year":"2025"},{"key":"10.1016\/j.jcf.2026.09.007_bib0002","series-title":"Data query","year":"2026"},{"issue":"5","key":"10.1016\/j.jcf.2026.09.007_bib0003","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.09.007_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108171","article-title":"Impact of availability of a highly effective cystic fibrosis treatment (elexacaftor\/tezacaftor\/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US","volume":"245","author":"Merlo","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2026.09.007_bib0005","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jcf.2025.06.005","article-title":"Elexacaftor\/tezacaftor\/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US","volume":"24","author":"Burdis","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2026.09.007_bib0006","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.jcf.2026.09.007_bib0007","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2026.09.007_bib0008","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2026.09.007_bib0009","unstructured":"MedGen. Tacrolimus response. (https:\/\/www.ncbi.nlm.nih.gov\/medgen\/831835)."},{"issue":"1","key":"10.1016\/j.jcf.2026.09.007_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jcf.2026.09.007_bib0011","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcf.2025.03.010","article-title":"Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant","volume":"24","author":"Guimbellot","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.09.007_bib0012","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"6","key":"10.1016\/j.jcf.2026.09.007_bib0013","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.TP.0000054689.50879.36","article-title":"Four-year follow-up of body compostion in lung transplant patients","volume":"75","author":"Kyle","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.jcf.2026.09.007_bib0014","first-page":"20","article-title":"Safety and extrapulmonary effects of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis following lung transplantation: a systematic review and meta-analysis","volume":"59","author":"Venditto","year":"2026","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2026.09.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2025.100210","article-title":"Evaluation of elexacafor\/tezacaftor\/ivacaftor therapy after lung transplantation in cystic fibrosis: the Dutch national KOALA study","volume":"7","author":"van Gemert","year":"2025","journal-title":"JHLT Open"},{"issue":"6","key":"10.1016\/j.jcf.2026.09.007_bib0016","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MCP.0000000000001110","article-title":"Elexacaftor-tezacaftor-ivacaftor use after solid organ transplant","volume":"30","author":"Kapnadak","year":"2024","journal-title":"Curr Opin Pulm Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:50:30Z","timestamp":1790538630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326037410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":16,"alternative-id":["S1569199326037410"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.09.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}